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Tyrosine kinases play crucial roles in cellular development and tumorigenesis. Tyrosine kinase inhibitors (TKIs) are effective and
widely used drug molecules in targeted cancer therapies. Altered expressions of protooncogenes and tumor suppressor genes
after DMBA (7,12-dimethylbenz[a]anthracene) treatment have been described as early markers of tumor induction; however
their tissue-specific effects remain still unclear. Our study was aimed at examining the short-term possible antineoplastic and
chemopreventive effects of a TKI compound (imatinib mesylate) on a DMBA-induced mouse tumor model. In addition, we also
investigated the tissue-specific expressions ofHras, Kras, Myc, and Trp53 genes in the brain, bone marrow, spleen, liver, abdominal
lymph nodes, thymus, lungs, and kidneys, respectively. 24 hours after the imatinib mesylate injection, we observed significant Kras
downregulation in the bone marrow and lung of the DMBA-treated mice. Moreover, the mRNA expression ofMyc was also found
to be decreased significantly in the spleen. Interestingly, while Trp53 expression was significantly increased in the lung, it was
decreased in the other tissues. However, there was also a tendency in the decreasedMyc level in the bone marrow, brain, kidneys,
lungs, and lymph nodes and in the decreasedHras level in the bonemarrow, kidneys, and lungs, although no significant differences
were observed. Our findings indicate rapid tissue-specific impact of imatinib mesylate on DMBA-induced gene expression in vivo,
supporting the chemopreventive potential of imatinib mesylate in cancer.
1. Introduction
Protein kinases (PKs) play pivotal roles in cellular pro-
cesses such as metabolism, proliferation, apoptosis, immune
response, or nervous system functions. PKs regulate enzyme
activity by phosphorylating cellular proteins [1] and their dys-
regulation may lead to pathological conditions, i.e., different
types of cancers or inflammatory diseases. Therefore, PKs
have become one of the most extensively investigated drug
targets in the past two decades [2]. To date, the human PK
gene family consists of 518 members and can be categorized
into nine groups. Among them, tyrosine kinases (TKs)—and
their inhibitor molecules—are the most promising targets of
cancer studies [3]. TKs are classified as receptor and non-
receptor tyrosine kinases. Receptor tyrosine kinases (RTKs)
are transmembrane proteins consisting of an extracellular
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ligand-binding domain and an intracellular kinase domain
[4]. Nonreceptor tyrosine kinases can be found in the cytosol
and nucleus or in the inner part of the plasma membrane,
participating in the regulation of cell proliferation or differ-
entiation [5]. The activation of TKs is under tight control.
Their kinase activity is low in nonproliferating cells. On the
contrary, TK expression is extremely increased in cancer
cells, caused by ligand or receptor overexpression by various
mechanisms [6–11].
Imatinib was the first small-molecule TKI that accom-
plished a remarkable clinical success in the treatment of
chronic myeloid leukemia (CML). Imatinib mesylate inhibits
the constitutively active BCR-Abl protein kinase that is
responsible for the constant proliferation of myeloid cells
[12]. Druker et al. reported that imatinib produced a 92-
98% decrease in the number of colonies from BCR-Abl cells,
while having minimal effect on normal cells [13]. Imatinib
targets further protein kinases, including the stem cell fac-
tor receptor (c-kit) and the platelet-derived growth factor
receptor (PDGFR), whose inhibition might have potential
implications for the treatment of several malignancies [14].
Imatinib treatment is usually well-tolerated; however, side
effects may develop, e.g., edema, nausea, skin rash or moder-
ate myelosuppression [15]. Resistance to imatinib can occur
within months or years after the beginning of the treatment.
Several mechanisms of resistance have been discovered,
categorized as BCR-Abl-dependent (like point mutation in
the protein kinase domain of Abl, amplification, or overex-
pression of the gene) [16]) or independent (decreased drug
uptake, increased efflux, or upregulation of secondary signal
transduction pathway elements, such as Ras-Raf-MEK-ERK)
[17]).
Other tyrosine kinase inhibitors include sunitinib for
metastatic renal cell carcinoma [18], sorafenib for clear-cell
renal carcinoma [19], gefitinib for advanced non-small cell
lung cancer [20], erlotinib for the treatment of pancreatic
cancer [21], lapatinib for women with advanced breast cancer
[22], pazopanib for locally advanced or metastatic renal
cell carcinoma [23], vandetanib for advanced non-small-cell
lung cancer [24], and axitinib as a second line therapy for
metastatic renal cell carcinoma [25]. This class of small-
molecule drugs offers enormous promise for targeted man-
agement of malignant diseases. A growing body of evidence
suggests that suppressing the secondary signal transduction
pathway intensity by TKI-s might be promising target in
antitumor therapy [26]. Oncogenes and tumor suppressor
genes play essential roles in tumorigenesis. The ‘classical’
mammalianRASprotooncogenes (HRAS, KRAS, andNRAS),
the MYC protooncogene, and the tumor suppressor TP53
gene are of great relevance in tumorigenesis. Ras proteins are
small GTP-ase transcription factors that play a regulatory role
in MAPK and PI3K secondary signal transduction pathways.
Their disturbed functions result in cell proliferation and death
[27]. Mutant Ras proteins are constitutively active, leading
to uncontrolled cell proliferation, and can be associated
with nearly one-third of human cancers such as pancreatic,
epidermal, lung, colorectal cancers, or multiple myeloma
[28]. Myc is a member of the MYC oncogene family (Myc,
Mycn, and Mycl) that encodes a phosphoprotein being able
to transform cells through multiple pathways [29, 30]. Asso-
ciatedwith almost 70% of human cancers [31],Myc is amaster
regulator of tumorigenesis and development through mod-
ulating the activity of genes in cell proliferation, apoptosis,
tumor suppression, DNA repair, angiogenesis, and invasion
[32]. P53 is the most extensively studied tumor suppressor
protein, since its gene is mutated nearly in half of the human
tumors [33]. The majority of mutations occur in the DNA-
binding domain; however, mutations may be observed in
every region of the human TP53 gene [34, 35]. Two forms of
TP53mutation exist: ‘loss-of-function’ and ‘gain-of-function’
mutations [36]. ‘Loss-of-function’ mutations lead to loss of
oncosuppressive activity, while ‘gain-of-function’ mutations
may result in numerous different effects including enhanced
tumor cell invasion and motility [37], chemoresistance [38],
proliferation [39], and enhanced cell survival [40].
In a previous study, we investigated the antineoplastic
and chemopreventive properties of four tyrosine kinase
molecules in the liver, lung, bone marrow, and kidney of
a DMBA (7,12-dimethylbenz[a]anthracene) induced mouse
preclinical tumor model by examining the expression ofHras
and Trp53 genes. DMBA is a widely used polycyclic aromatic
hydrocarbon chemical carcinogen that initiates chemical
carcinogenesis by inducing various oncogenic mutations
resulting in lung tumor, squamous cell carcinoma, and vas-
cular tumors (hemangiomas), as well as intestinal, mammary,
uterine, or hematologic tumors [41, 42].The results suggested
that chalcone analogues, as intermediary compounds of the
flavonoid biosynthetic pathway, and plant derivatives may
possess potential chemopreventive effects [43].
In this study, we assessed the short-term tissue-specific
effects of imatinib mesylate on the expression of Hras, Kras,
andMyc and Trp53 genes in the bonemarrow, brain, kidneys,
liver, lungs, lymph nodes, spleen, and thymus of DMBA-
treated mice.
2. Materials and Methods
2.1. Experimental Animals. Six- to eight-week-old (25±5 g)
conventionally raised NMRI inbred mice (n=12, 6 males
and 6 females in each group) were involved in our study,
which was approved by the Animal Experiment Committee
of University of Pe´cs (BA 02/2000-16/2011). The mice were
housed six animals per cage at an ambient temperature under
a 12h:12h light:dark cycle with ad libitum access to chow food
and water.
2.2. Treatment Group Assignment. Three experimental sets
were created for the experimental agents (Figure 1). The first
set of animals was treated intraperitoneally (i.p.) with vehicle
(corn oil) and served as a negative control group. The second
set of mice (positive control) was treated i.p. with a 20mg/kg
dose of DMBA dissolved in corn oil (both compounds were
purchased from Sigma Aldrich, Budapest, Hungary). In the
third group (experimental set), animals were simultaneously
treated i.p. with 10mg/kg imatinib mesylate (4-[(4-methyl-
1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-
pyrimidinyl]amino]-phenyl]benzamide methanesulfonate,
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Figure 1: Experimental design. Six- to eight-week-old (n=36) conventionally raised NMRI inbred mice were divided randomly into three sets:
the negative control group was i.p. treated with the vehicle (corn oil) (1st set, n=12), the positive control group (2nd set, n=12) was treated i.p.
with a 20mg/kg body weight dose DMBA (7,12-dimethylbenz[a]anthracene), and the experimental group (3rd set, n=12) was treated i.p. with
10mg/kg imatinib mesylate and 20mg/kg DMBA. Animals were autopsied 24 hours after treatment, and organs were dissected and stored
for further analysis.
Novartis Pharma GmbH product (Glivec), and 20mg/kg
DMBA dissolved in corn oil. Mice were sacrificed 24
hours after the injections, and organs (liver, spleen, kidney,
lung, thymus, lymph node, bone marrow, and brain) were
harvested and snap-frozen in liquid nitrogen and then stored
at - 80∘C for further use.
2.3. RNA Extraction. mg tissue samples of each organ from
the respective groups were homogenized in MagNA Lyzer
Green Beads tubes (Roche (Hungary) Ltd.) using the MagNA
Lyzer instrument (Roche (Hungary) Ltd.). Total RNA was
isolated from the tissue lysates using the EXTRAzol RNA
extraction kit (Invitrogen Life Technologies Magyarorsza´g
Kft). The RNA quality was assessed by absorption
measurement at 260/280 nm (A260/A280 was >1.8).
2.4. Gene Expression Investigations. One-step PCR including
reverse transcription and target amplification was performed
using Kapa SYBR FAST One-step RTqPCR Kit (Kapa
Biosystems) on a LightCycler 480 qPCR platform with a 96-
well format.The specific primers (IDT) formouse tumor sup-
pressor genes (Hras, 5󸀠-AATTGGGGGAGCAAGGACAT-
3󸀠); (Kras, 5󸀠-TATCCTGCTTCCCATCAGTGTTC-3󸀠 );
(Myc, 5󸀠-GTTGTGCTGGTGAGTGGAGA-3󸀠 ); (Trp53, 5󸀠-
CTTCACTTGGGCCTTCAAAA-3󸀠) and for a housekeeping
gene (Gapdh, 5󸀠-CACATTGGGGGTAGGAACAC-3󸀠) were
used in the quantitative amplification.
RT-qPCR was initiated by 5min. and 3min. incubations
at 42∘C and 95∘C, respectively, followed by 50 cycles (95∘C for
10 s, 55∘C for 20 s, and 72∘C for 20 s)with a fluorescent reading
taken at the end of each cycle. Each run was completed with
a melting curve analysis (95∘C for 5 s, 65∘C for 60 s, and 97∘C
∞) to confirm the specificity of amplification. Fluorescent
values were calculated following the ΔΔCp method on Exor
4 software (Roche (Hungary) Ltd.) and gene expressions are
reflected as relative quantification results.
2.5. Data Analysis. Statistical analyses were performed using
R software (http://www.r-project.org) and SPSS 21.0 software
(SPSS Inc., IL, USA). The differences in mRNA expression
levels were calculated using a two-tailed Student’s t-test
and were considered to be significant when p<0.05. Gene-
gene interaction networks to demonstrate the relationship
between genes in different organs/experimental sets were
generated by the GeneMania Cytoscape 3.4.0 application.
Physical, coexpression, and gene-gene interactions were
evaluated [44]. Heat map was constructed using Gene-E ver-
sion 3.0.204 (http://www.broadinstitute.org/cancer/software/
GENE-E/index.html).
3. Results
3.1. Gene Expression. Gene expression patterns of the three
experimental sets are shown on Figures 2 and 3. Importantly,
we found no gender-specific differences in the gene expres-
sion patterns.
3.1.1. Bone Marrow. In the bone marrow, DMBA injection
decreased the expressions of Hras, Kras, and Myc, respec-
tively, and increased Trp53 expression. DMBA+imatinib
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Figure 2: Heat map of gene expression patterns compared to the negative control. Blue boxes represent negative (down) regulation, while red
boxes indicate positive (up)regulation of the gene expression.
mesylate administration further decreased the Hras, Kras,
and Myc expressions. Compared to the negative control,
significantly lowerKras expressions were found in the second
(p<0.05) and third sets of mice (p<0.05).The combined treat-
ment also decreased the expression of the tumor suppressor
Trp53 to a significant extent (p<0.05), first (control) versus
third (DMBA + imatinib mesylate) set.
3.1.2. Brain. Compared to the negative controls, DMBA
administration resulted in increased gene expressions in
the brain; however, these changes were found to be non-
significant. Combined administration ofDMBAand imatinib
mesylate decreased the expressions of the studied genes;
however, these alterations were not significant either.
3.1.3. Kidney. DMBA increased the expressions of the Hras,
Kras, and Myc, respectively, and the expression of the Trp53,
as well. The simultaneous administration of DMBA and TKI
reduced the expression of all the investigated genes.
3.1.4. Liver. In the liver, DMBA administration lowered the
expressions of Hras, Kras, Myc, and Trp53, respectively. As
a result of the combined DMBA+TKI administration, the
decrease in the expression of these genes became reduced.
3.1.5. Lung. In the lung, mRNA expressions of the Kras
(p<0.05), Myc, and Trp53 genes were increased, while the
Hras expression was decreased following the DMBA injec-
tion. Simultaneous treatment with DMBA and TKI led to
decreased the expression of protooncogenes (Hras, Kras, and
Myc) and increased Trp53mRNA levels.
3.1.6. Lymph Nodes. In the lymphoid tissues, DMBA
decreased the Hras expression and increased the Kras
and Trp53 expressions, that remained unchanged after the
combined administration with DMBA+TKI. However, the
expression ofMyc was increased by DMBA and decreased as
a result of DMBA+TKI combination. However, this change
in mRNA expression was not statistically significant.
3.1.7. Spleen. Hras and Kras gene expressions were decreased
after DMBA injection, although they did not change
after DMBA+TKI administration. In turn, DMBA induced
increased expressions of Myc (p<0.05) and decreased Trp53
expressions after treatment (DMBA+TKI).
3.1.8. Thymus. In the thymus, DMBA increased the expres-
sions of Kras, Myc and Trp53, respectively, while decreasing
theHras expression. As a result of combined administration of
DMBA+imatinib mesylate, the expressions ofKras and Trp53
were found to be reduced compared to the negative control.
Additionally, the expression ofMyc showed an increase, while
the expression ofHras remained unaltered after the combined
injections.
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Figure 3: Gene expression pattern of experimental groups in different organs. ∗ p<0,05.
3.2. Gene Network. Figure 4 shows the fold regulation of gene
expressions in selected organs and their predicted interac-
tions among the different regulatory genes. We observed sig-
nificant alterations in gene expressions in the bone marrow,
lung, and spleen. Our network analysis revealed that Hras,
Kras, and Myc protooncogenes and Trp53 tumor suppressor
gene have extensive connections to other regulatory genes.
Zhx2 (also known as RAF) is a homodimeric transcription
factor that belongs to the zinc fingers and homeoboxes gene
family [45], Abi1 (abl interactor 1) is an adaptor protein
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Figure 4: A gene-gene interaction network presenting the correlation among the fold regulation of Kras, Hras, Myc, and Trp53 genes in the
represented organs and their predicted interactions with 10 functionally related genes. The 10 correlated genes were obtained using the
GeneMania application of Cytoscape; level of significance: ∗ (p < 0.05).
that facilitates several signal transduction pathways, reg-
ulates actin polymerization and cytoskeleton remodeling,
and therefore has a role in cell proliferation [46]. Tcf4
(transcription factor 4) is essential for neuronal development
[47], and Tsc2 (TSC complex subunit 2) gene codes a tumor
suppressor protein (tuberin), mutation of which (together
with mutation of hamartin, coded by Tsc1) causes tuberous
sclerosis complex [48].Huwe1 encodes an E3 ubiquitin ligase
protein that is responsible for ubiquitination and degradation
of the antiapoptotic protein Mcl1 (myeloid cell leukemia
sequence 1 (Bcl2-related)) [49]. Cdkn2a (cyclin dependent
kinase inhibitor 2a) is an important tumor suppressor gene,
having at least three alternative spliced variants that code
twoCDK4 inhibitors and one p53 stabilizer protein, therefore
playing a pivotal role in cell cycle G1 control [50].Nde1 (nudE
neurodevelopment protein 1) gene codes a protein that has
essential role in microtubule organization, mitosis, and neu-
ronal migration, mutation of which can be associated with
lissencephaly [51].Kmt5a (lysine methyltransferase 5a) codes
a protein that is a transcriptional repressor and is important
for cell proliferation and chromatin condensation [52].Mcm4
(minichromosomemaintenance complex component 4) gene
codes a protein that is highly conserved and important for ini-
tiation of eukaryotic genome replication [53]. Eif4e (eukary-
otic translation initiation factor 4E) functions as a protoonco-
gene; its product helps the initiation of translation [54].
4. Discussion
Several studies have demonstrated the role of tyrosine kinases
in human diseases [55, 56]. Consequently, tyrosine kinases
have become one of the main areas of pharmacological
experiments intended to develop targeted drugs [57]. Protein
tyrosine kinase inhibitors are small molecules that are able
to diffuse through the cell membrane targeting cytoplasmic
kinases or the intracellular domain of receptor tyrosine
kinases. TKIs are currently booming and are widely used
in cancer cure either in the form of monotherapy or in
combination with other chemotherapeutic agents [58].
In our present study, we investigated the potential chemo-
preventive effect of imatinib mesylate that is the first small-
molecule tyrosine kinase inhibitor used inCMLand gastroin-
testinal stromal tumor (GIST) [59, 60]. To date, our study is
among the first ones to examine the possible preventive effect
of imatinib mesylate by studying the alterations in DMBA-
induced gene expression levels and trying to put the results
into the gene network of different protooncogenes (Hras,
Kras, and Myc) and a tumor suppressor gene (Trp53) in a
short-term experiment. The outcomes shown here suggest
that imatinib mesylate might have a possible mitigating role
in diseases beyond CML and GIST.
Major results of the present study include that short-
term DMBA treatment (i) elevated the expression of all the
three protooncogenes (Hras, Kras, and Myc) in the brain
and kidneys; (ii) increased the level of Kras and Myc in the
lung, lymph nodes and thymus; (iii) increased the expression
of the tumor suppressor gene Trp53 that can be considered
an adaptive physiologic countermeasure in response to a
chemical carcinogen.These phenomena have been previously
described by several investigations, concluding that DMBA is
a potent inducer of chemical carcinogenesis and can be used
for studying different types of malignant tumors. DMBA is a
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polyaromatic hydrocarbon similar to hydrocarbons to which
humans can be exposed. DMBA causes point mutations in
protooncogenes like Hras that is common in human carci-
nomas [61]. In the bone marrow and liver, DMBA decreased
the expression level of Hras, Kras, andMyc. This observation
might be explained by the fact that DMBA is a carcinogenesis
inducer, and it is usually applied simultaneously with a
carcinogenesis promoter, e.g., 12-O-tetradecanoylphorbol 13-
acetate (TPA) [62].Therefore, in case of the bonemarrow and
liver, DMBA might not be enough for complete tumorige-
nesis. In the spleen, the elevated level of Myc was the only
prominent and significant alteration in the gene expression
pattern. Several studies have elucidated the role of Myc
in tumorigenesis. Probably the best-established association
is that nearly every case of Burkitt’s lymphoma involves
rearrangement and therefore overexpression of Myc with a
regulatory element of immunoglobulin heavy or light chains
or other nonrandom somatic mutations of the gene [63, 64].
The results of the aforementioned studies correlate with our
finding of elevated expression of Myc in the spleen and
lymph nodes as a consequence of DMBA treatment. The
increased expression of the examined four genes gain more
importance in the context of their extensive gene network.
Zhx2 (also known as RAF) has previously been associated
with Hodgkin lymphoma [65] and hepatocellular carcinoma
[66]; Abi1 (abl interactor 1) has a role in colorectal carcinoma
development and invasion [67] and also in neuroblastoma
propagation [68]. Aberrant function of Tcf4 (transcription
factor 4) has been reported in glioblastoma [69] and in
colorectal tumors [70]. Tsc2 (TSC complex subunit 2) gene
codes a tumor suppressor protein (tuberin), mutation of
which have been associated with tumors in the brain, lungs,
kidneys, skin, heart, uterus, and eyes [71, 72].Huwe1 encodes
an E3 ubiquitin ligase protein that is required for the
development of colorectal carcinoma and ovarian tumors
[73, 74]. Cdkn2a (cyclin dependent kinase inhibitor 2a) is
an important tumor suppressor gene predisposing to several
tumors, e.g., urothelial carcinoma, hereditary melanoma,
pancreas cancer, or non-small-cell lung cancer [75–77]. Nde1
(nudE neurodevelopment protein 1) gene codes a protein that
has essential role in microtubule organization and mitosis,
and recent studies have elucidated its potential role in acute or
chronic myeloid leukemia [78, 79].Mcm4 (minichromosome
maintenance complex component 4) has been reported to
be upregulated in ovarian cancer, skin cancer, or esophageal
carcinoma [80–82]. Eif4e (eukaryotic translation initiation
factor 4E) functions as a protooncogene; its product has
been suggested to regulate expression of proteins that are
crucial for cell cycle progression, cell survival, andmotility. A
growing body of evidence implicates this translational factor
in cell transformation, tumorigenesis, or tumor progression,
e.g., in case of prostate cancer, lymphomas, CML, or lung
cancers [83].
As it is suggested by the extensive gene network of the
examined genes, cancer development involves more than one
transforming events and the interaction of several oncogenes
and tumor suppressor genes. This network and series of
events offers numerous opportunities to effectively influence
the process of tumorigenesis.
In the lungs, the expression of protooncogenes (Hras,
Kras, and Myc) and their connections to other genes coding
transcription factors or cell proliferation regulators (e.g.,
Tcf4, Abi1, and Zhx2) prominently decreased as a result of
the short-term combined DMBA+TKI treatment, while the
expression of Trp53 gene increased. Comparing to the nega-
tive control, the decrease in Kras expression was significant.
In the bone marrow, DMBA+TKI combined treatment
significantly decreased the expression and gene interactions
of the Kras and Trp53.
DMBA+TKI treatment could significantly decrease the
DMBA-induced increase in the expression and gene inter-
actions of Myc protooncogene. The expression of the tumor
suppressor Trp53 also decreased following the combined
treatment; however, this decrease was not significant.
Outcomes of our short-term experiment suggest that pro-
tein tyrosine kinase inhibitor treatment (imatinib mesylate)
simultaneously administered with the chemical carcinogen,
DMBA,might have an impact on the expression pattern of the
examined protooncogenes (Hras, Kras, and Myc) and tumor
suppressor gene (Trp53), therefore on the tumorigenesis,
controlled by these genes.
Imatinib mesylate is a well-known small-molecule
inhibitor of tyrosine kinases. In our study, this drug was able
to decrease significantly the expression of Kras oncogene in
the bone marrow and in the lung, as well as the expression
of Myc oncogene in the spleen. Additionally, Myc mRNA
expressions were tended to be lowered in the bone marrow,
brain, kidneys, lungs, and lymph nodes and we also observed
tendencies in the HrasmRNA expressions to be decreased in
the bonemarrow, kidneys, and lungs, although these changes
were not statistically significant. The reduced expression of
these oncogenes may be attributed to the kinase inhibitor
effect of imatinib mesylate, as described by other recent
studies. Among others, Lorri Puil et al. reported that BCR-
Abl was able to activate Ras signaling in CML, by creating
a direct link between Grb2 and mSos1 that are responsible
for the conversion of inactive GDP-bound form of Ras into
the active, GTP-bound form. Therefore, inhibiting BCR-Abl
kinase activity may downregulate Ras signaling in CML [84].
BesidesRas signaling, BCR-Abl kinase can indirectly acti-
vate Myc either through the Janus-activated kinase 2 (JAK2)
pathway [85] or by the mitogen-activated protein kinase
(MAPK) pathway [86]. It is tempting to speculate that ima-
tinib might have decreased the expression ofMyc well before
itsDMBA-induced overexpression. CallahanR. et al. revealed
that imatinibmesylate was able to induce complete regression
of mammary tumor and restore lobuloalveolar development
and lactation by inhibiting Notch4 andMyc signaling, which
result also support the idea of therapeutic potential of
imatinib mesylate, other than CML and GIST [87].
PDGF isoforms and their receptors (PDGFRs) are con-
sidered as prototypes of growth factors and receptor tyrosine
kinases for more than 25 years. They are essential for nor-
mal gastrulation and cranial, neuronal, cardiac, pulmonary,
intestinal, gonadal, hematological, skin, renal, and skeletal
development, as well as for hematopoiesis, through the
secondary signal transduction pathway, including activa-
tion of Ras and the downstream Raf and MAPK cascades
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[88]. However, overexpression or mutational events in the
PGDFR gene may drive tumor development and progression
[89]. Recent studies have elucidated the role of PDGFRs
in the evolution of different nervous system tumors, i.e.,
glioblastoma [90], ependymoma [91], meningioma [92],
and schwannoma (in which PDGFR mutation is usually
associated with c-kit overactivation [93]). In addition to
brain tumors, the role of mutant PDGFR has numerously
been emphasized in other malignant diseases, like dermatofi-
brosarcoma protuberans [94], gastrointestinal stromal tumor
(GIST) [95], osteosarcoma [96], alveolar rhabdomyosarcoma
[97], chronic myeloid leukemia (CML) [98], prostate cancer
[99], liver cancer [100], non-small-cell lung cancer [101],
and colorectal cancer [102] and in breast cancer [103]. There
have been numerous attempts to inhibit the activity of
PDGFRs, including tyrosine kinase inhibitors, like imatinib
or sorafenib, and also several antibodies targeting the differ-
ent PDGF isoforms or the receptors themselves to prevent
their activation. In general, antibodies aremuchmore specific
therapeutic tools; however, their administration is expen-
sive and sometimes inconvenient. Tyrosine kinase inhibitors
are not specific; they have the potential to inhibit more
kinases—and in this way have more adverse effects—as ima-
tinib is able to inhibit PDGFRs, Abl kinases, and the stem cell
receptor c-kit, but in cancer treatment, it can be advantageous
to target more than one component of tumorigenesis [89].
Kras, Hras, and Myc are the executive elements of
numerous oncogenic pathways, so they can be favorable to
inhibit a common point of tumorigenesis by one molecule.
p53 is the best characterized tumor suppressor protein, as it
is able to induce cell cycle arrest or cell death in response to
hypoxia and incorrigible genetic mutations, while mutations
of TP53 gene have been associated with more that 50%
of human tumors [104]. There is growing evidence that
these mutations are ‘loss-of-function’ mutations; however,
missense mutations may result in simultaneous gain of
functions that have usually detrimental effect to the cell
[105]. Numerous studies have reported that mutant p53
played a key role in tumor development, progression, and
invasion of several cancer types, e.g., in case of breast cancer
[106], lung cancer [107], colorectal cancer [108], different
brain tumors, and gastric adenocarcinoma [109]. In our
present study, short-term imatinib mesylate treatment
administered simultaneously with DMBA resulted in a
prominent increase in the Trp53 expression in the lung,
while decreasing it in all the other tissues.These data indicate
a possible ‘gain-of-function’ mutation in the gene of the
tumor suppressor p53 protein and that imatinib mesylate
attempted to decrease the level of this aberrant protein.
Based on our recent and previous findings we suggest that
imatinib mesylate is a promising chemotherapeutic agent for
prevention and management of several malignant tumors by
decreasing the mRNA expression of the protooncogenes and
the mutant Trp53 gene.
5. Conclusion
The outcomes of the present study demonstrate that imatinib
mesylate decreases themRNAexpressions ofHras, Kras,Myc,
and Trp53 genes in certain organs after 24 hours of a single
dose of TKI treatment in a DMBA-induced mouse tumor
model. These results suggest its preventive and curative roles
in malignant diseases.
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